Law360 (December 15, 2020, 9:33 PM EST) -- Drugmakers, retailers and distributors targeted in the multidistrict litigation over heartburn medication Zantac told a Florida federal court on Tuesday that plaintiffs' state law claims over alleged design and labeling defects are preempted by federal law.
In day two of a two-day videoconference hearing on various motions to dismiss, the defendants leaned on two U.S. Supreme Court decisions, PLIVA Inc. v. Mensing and Mutual Pharmaceutical Co. v. Bartlett, to argue that the plaintiffs' claims about a cancer-causing chemical in Zantac and its generic equivalent ranitidine are preempted by federal law because the defendants would have had to ask for permission or...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!